"emovis ist das erfahrene und patientenfreundliche Studienzentrum im Herzen Berlins. Wir beraten und betreuen alle Menschen, die an einer Studie bei uns teilnehmen möchten, gerne. Interessieren Sie sich für die Teilnahme an einer klinischen Studie?? Von uns erhalten Sie eine Patienteninformationsschrift, die Sie umfassend informiert. Außerdem laden wir Sie zu einem Gespräch mit einem unserer Prüfärzte ein. In diesem ausführlichen, ersten Gespräch, werden alle offenen Fragen geklärt. Auf unserer Website unter Aktuelle Studien finden Sie alle Studien aufgelistet, die wir zur Zeit oder demnächst durchführen."

During the past decade, Emovis GmbH conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 25 clinical trials were completed, i.e. on average, 73.5% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 14 clinical trials were completed. i.e. 70% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Emovis GmbH" #1 sponsor was "Pfizer" with 8 trials, followed by "Shire" with 6 trials sponsored, "Bayer" with 5 trials sponsored, "Boehringer Ingelheim" with 5 trials sponsored and "Janssen Research & Development, LLC" with 5 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Emovis GmbH" #1 collaborator was "Analyze & Realize" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "FGK Clinical Research GmbH" with 1 trials as a collaborator and "GlaxoSmithKline" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Emovis GmbH" are "Alzheimer's Disease" (4 trials), "Depressive Disorder, Major" (3 trials), "Major Depressive Disorder" (3 trials), "Alopecia Areata" (2 trials) and "Alzheimer Disease" (2 trials). Many other conditions were trialed in "Emovis GmbH" in a lesser frequency.

Most popular intervention types in "Emovis GmbH" are "Drug" (44 trials), "Biological" (7 trials), "Other" (5 trials), "Behavioral" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (25 trials), "BAY1817080" (2 trials), "BI 409306" (2 trials), "Daridorexant 25 mg" (2 trials) and "Daridorexant 50 mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Emovis GmbH" are 46 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Emovis GmbH". undefined are not yet recruiting, 3 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 35 completed trials in Emovis GmbH, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Emovis GmbH, 1 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".